A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 16,408 shares of XENE stock, worth $628,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,408
Previous 16,408 -0.0%
Holding current value
$628,590
Previous $645,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$36.12 - $43.96 $288 - $351
-8 Reduced 0.05%
16,408 $645,000
Q2 2024

Jul 29, 2024

SELL
$36.25 - $43.75 $538,820 - $650,300
-14,864 Reduced 47.52%
16,416 $640,000
Q1 2024

Apr 25, 2024

BUY
$42.66 - $50.04 $669,591 - $785,427
15,696 Added 100.72%
31,280 $1.35 Million
Q4 2023

Jan 30, 2024

BUY
$28.7 - $46.46 $113,680 - $184,028
3,961 Added 34.08%
15,584 $717,000
Q3 2023

Oct 25, 2023

BUY
$34.16 - $39.73 $83,008 - $96,543
2,430 Added 26.43%
11,623 $397,000
Q2 2023

Aug 07, 2023

SELL
$34.84 - $43.54 $3,971 - $4,963
-114 Reduced 1.22%
9,193 $353,000
Q1 2023

May 08, 2023

SELL
$33.46 - $40.35 $4,416 - $5,326
-132 Reduced 1.4%
9,307 $333,000
Q4 2022

Feb 01, 2023

BUY
$33.06 - $39.43 $91,642 - $109,299
2,772 Added 41.58%
9,439 $372,000
Q2 2022

Aug 09, 2022

SELL
$25.44 - $35.16 $1,679 - $2,320
-66 Reduced 0.98%
6,667 $203,000
Q1 2022

Apr 21, 2022

SELL
$25.09 - $33.13 $71,054 - $93,824
-2,832 Reduced 29.61%
6,733 $206,000
Q4 2021

Feb 01, 2022

BUY
$15.6 - $35.4 $83,678 - $189,885
5,364 Added 127.68%
9,565 $299,000
Q3 2021

Nov 15, 2021

BUY
$14.86 - $19.45 $1,634 - $2,139
110 Added 2.69%
4,201 $64,000
Q1 2021

May 03, 2021

BUY
$13.65 - $21.31 $55,842 - $87,179
4,091 New
4,091 $73,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.